Literature DB >> 2769157

The inter-relationships between ovarian-independent growth, tumorigenicity, invasiveness and antioestrogen resistance in the malignant progression of human breast cancer.

R Clarke1, N Brünner, E W Thompson, P Glanz, D Katz, R B Dickson, M E Lippman.   

Abstract

Among the processes contributing to the progressive acquisition of the highly malignant phenotype in breast cancer are ovarian-independent growth, antioestrogen resistance and increased metastatic potential. We have previously observed that increased invasiveness and development of ovarian-independent growth occur independently. In an attempt to define the inter-relationships between these processes further, we have compared the phenotypes of ovarian-independent, invasive and antioestrogen-resistant sublines of the ovarian-dependent human breast cancer cell line MCF-7. Cells acquiring ovarian-independent growth can retain sensitivity to anti-oestrogens. One clone of MCF-7 cells selected for stable antioestrogen resistance has become non-tumorigenic but its invasive potential remains unaltered. Thus, acquisition of some characteristics of the progressed phenotype can occur independently. This phenomenon of independent parameters in phenotypic progression could partly explain the considerable intra- and intertumour heterogeneity characteristic of breast tumours.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2769157     DOI: 10.1677/joe.0.1220331

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  17 in total

1.  IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.

Authors:  Yanxia Ning; Rebecca B Riggins; Jennifer E Mulla; Haniee Chung; Alan Zwart; Robert Clarke
Journal:  Mol Cancer Ther       Date:  2010-05       Impact factor: 6.261

2.  Molecular analysis of two mammary carcinoma cell lines at the transcriptional level as a model system for progression of breast cancer.

Authors:  S Schiemann; M Schwirzke; N Brünner; U H Weidle
Journal:  Clin Exp Metastasis       Date:  1998-02       Impact factor: 5.150

3.  Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells.

Authors:  A H Ree; K Bjørnland; N Brünner; H T Johansen; K B Pedersen; A O Aasen; O Fodstad
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

Review 4.  Hormone resistance, invasiveness, and metastatic potential in breast cancer.

Authors:  R Clarke; E W Thompson; F Leonessa; J Lippman; M McGarvey; T L Frandsen; N Brünner
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells.

Authors:  Robert Clarke; Ayesha N Shajahan; Rebecca B Riggins; Younsook Cho; Anatasha Crawford; Jianhua Xuan; Yue Wang; Alan Zwart; Ruchi Nehra; Minetta C Liu
Journal:  J Steroid Biochem Mol Biol       Date:  2009-03       Impact factor: 4.292

6.  1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro.

Authors:  C M Hansen; T L Frandsen; N Brünner; L Binderup
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

7.  The nude mouse as an in vivo model for human breast cancer invasion and metastasis.

Authors:  N Brünner; B Boysen; J Rømer; M Spang-Thomsen
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

8.  In vitro antineoplastic activity of C7-substituted mitomycin C analogues MC-77 and MC-62 against human breast-cancer cell lines.

Authors:  A Ghiorghis; A Talebian; R Clarke
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assays.

Authors:  S N Bae; G Arand; H Azzam; P Pavasant; J Torri; T L Frandsen; E W Thompson
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

10.  Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis.

Authors:  Anatasha C Crawford; Rebecca B Riggins; Ayesha N Shajahan; Alan Zwart; Robert Clarke
Journal:  PLoS One       Date:  2010-01-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.